The invention relates to a method of treating or diagnosing a disease state mediated by monocytes. The method utilizes a composition comprising a conjugate or complex of the general formula
A.sub.b-X
wherein the group A.sub.b comprises a ligand that binds to monocytes, and when the conjugate is being used for treatment of the disease state, the group X comprises an immunogen, a cytotoxin, or a compound capable of altering monocyte function, and when the conjugate is being used for diagnosing the disease state, the group X comprises an imaging agent.

The present invention provides certain compounds, or salts or solvates thereof, which can be used as matrix metalloproteinase-targeted inhibitors or imaging agents.

##STR00001##

The present invention relates to radiolabelled 4-(furo[3,2-c]pyridin-4-yl) derivatives and their use as radioactive tracers, and in particular their use as imaging agents.

##STR00001##

A chelator having the general structure (I) for chelating ra-diometals such as .sup.225Ac under mild conditions is provided. (I) The chelator can be coupled to a biological targeting moiety to facilitate targeted delivery of the chelated radiometal in a mammalian subject.

Aqueous formulations and kits of radiopharmaceutical compounds of general Formula (II) protected from radiolysis with stabilisers, such as L-methionine and gentisic acid, are disclosed, wherein the compounds are based on sarcophagine ligands coordinated to a radioisotope, such as 64-copper, and linked to a tetrazine group for reaction with tumour targeting antibodies having functional reactive groups such as trans-cyclooctene, processes of preparing said radioligand formulations, and uses thereof for radioimaging, diagnosing and treating cancer. ##STR00001##

The present invention relates to novel tetrazine compounds of formula I, wherein one of R.sub.1-R.sub.5 is .sup.18F, for use in pretargeted in vivo imaging. The compounds are suitable for use in click chemistry, i.e. reactions that join a targeting molecule and a reporter molecule. The invention further relates to precursors to formula I, wherein one of R.sub.1-R.sub.5 is SnR.sub.3, B(OR).sub.2, B(0H).sub.2. Formula (I).

##STR00001##

Aqueous formulations and kits of radiopharmaceutical compounds of general Formula (II) protected from radiolysis with stabilisers, such as L-methionine and gentisic acid, are disclosed, wherein the compounds are based on sarcophagine ligands coordinated to a radioisotope, such as 64-copper, and linked to a tetrazine group for reaction with tumour targeting antibodies having functional reactive groups such as trans-cyclooctene, processes of preparing said radioligand formulations, and uses thereof for radioimaging, diagnosing and treating cancer.

##STR00001##

Compositions and methods for visualizing tissue under illumination with near-infrared radiation, including compounds comprising near-infrared, closed chain, sulfo-cyanine dyes and prostate specific membrane antigen ligands are disclosed.

A targeted radiopharmaceutical of chemical Formula I, below, is disclosed wherein Q.sup.+3 is a

##STR00001## trivalent radioactive isotope ion; M is a proton (H+), an ammonium ion or an alkali metal ion; “g” is a number that is 1 to about 12; the boxed mAb MNPR-101 represents the chemically-bonded humanized mAb MNPR-101; and Y− is an optional anion present in an amount needed to balance the ionic charge. A pharmaceutical composition that comprises a theranostic effective amount of a Formula I targeted radiopharmaceutical dissolved or dispersed in a pharmaceutically acceptable diluent is also disclosed, as are a method for treating and/or diagnosing a mammalian host having a disease, disorder or condition characterized by undesired angiogenesis, tumor growth and/or tumor metastasis. A targeted pro-radiopharmaceutical construct similar to that of Formula I but without the radioisotope (Formula III) is also contemplated.

Compositions and methods for visualizing tissue under illumination with near-infrared radiation, including compounds comprising near-infrared, closed chain, sulfo-cyanine dyes and prostate specific membrane antigen ligands are disclosed.